{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:16:50Z","timestamp":1790140610614,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40273-021-01064-z","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T02:02:36Z","timestamp":1629079356000},"page":"1327-1341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment"],"prefix":"10.1007","volume":"39","author":[{"given":"Bassem","family":"Asker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghad","family":"Jawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabah","family":"Asreah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haydar","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Jassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muslim Abdelkareem","family":"Inaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiwa Abou","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Kozma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eid","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryony","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Darlington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"McEwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Sugrue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidar","family":"Jarallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"issue":"9401","key":"1064_CR1","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(03)15109-4","volume":"362","author":"T Poynard","year":"2003","unstructured":"Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003;362(9401):2095\u2013100.","journal-title":"Lancet"},{"issue":"10049","key":"1064_CR2","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","volume":"388","author":"JD Stanaway","year":"2016","unstructured":"Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081\u20138.","journal-title":"Lancet"},{"issue":"4","key":"1064_CR3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","volume":"65","author":"MCM Cheung","year":"2016","unstructured":"Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;65(4):741\u20137.","journal-title":"J Hepatol"},{"key":"1064_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2147\/CLEP.S132072","volume":"9","author":"S Hallager","year":"2017","unstructured":"Hallager S, Ladelund S, Christensen PB, Kj\u00e6r M, Thorup Roege B, Gr\u00f8nb\u00e6k KE, et al. Liver-related morbidity and mortality in patients with chronic hepatitis C and cirrhosis with and without sustained virologic response. Clin Epidemiol. 2017;9:501\u201316.","journal-title":"Clin Epidemiol"},{"issue":"1","key":"1064_CR5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","volume":"152","author":"P Nahon","year":"2017","unstructured":"Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017;152(1):142\u201356 (e2).","journal-title":"Gastroenterology"},{"key":"1064_CR6","volume-title":"Combating hepatitis B and C to reach elimination by 2030","author":"World Health Organisation","year":"2016","unstructured":"World Health Organisation. Combating hepatitis B and C to reach elimination by 2030. Geneva: World Health Organisation; 2016."},{"issue":"1","key":"1064_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12072-018-9902-x","volume":"13","author":"S Johnson","year":"2019","unstructured":"Johnson S, Aluzaite K, Taar A, Schultz M. Identifying barriers to treatment of HCV in the primary care setting. Hepatol Int. 2019;13(1):58\u201365.","journal-title":"Hepatol Int"},{"issue":"190","key":"1064_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.drugalcdep.2018.06.013","volume":"1","author":"MR Skeer","year":"2018","unstructured":"Skeer MR, Ladin K, Wilkins LE, Landy DM, Stopka TJ. \u201cHep C\u2019s like the common cold\u201d: understanding barriers along the HCV care continuum among young people who inject drugs. Drug Alcohol Depend. 2018;1(190):246\u201354.","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"1064_CR9","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.clinthera.2018.05.010","volume":"40","author":"SN Kapadia","year":"2018","unstructured":"Kapadia SN, Marks KM. Hepatitis C management simplification from test to cure: a framework for primary care providers. Clin Ther. 2018;40(8):1234\u201345.","journal-title":"Clin Ther"},{"issue":"5 Suppl. 3","key":"1064_CR10","first-page":"1","volume":"15","author":"DT Dieterich","year":"2019","unstructured":"Dieterich DT. A Simplified algorithm for the management of hepatitis C infection. Gastroenterol Hepatol. 2019;15(5 Suppl. 3):1\u201312.","journal-title":"Gastroenterol Hepatol"},{"issue":"1","key":"1064_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40261-016-0458-z","volume":"37","author":"T Ward","year":"2017","unstructured":"Ward T, Gordon J, Jones B, Bennett H, Webster S, Kalsekar A, et al. Value of sustained virologic response in patients with hepatitis C as a function of time to progression of end-stage liver disease. Clin Drug Investig. 2017;37(1):61\u201370.","journal-title":"Clin Drug Investig"},{"key":"1064_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.puhe.2016.08.002","volume":"141","author":"T Ward","year":"2016","unstructured":"Ward T, Gordon J, Bennett H, Webster S, Sugrue D, Jones B, et al. Tackling the burden of the hepatitis C virus in the UK: characterizing and assessing the clinical and economic consequences. Public Health. 2016;141:42\u201351.","journal-title":"Public Health"},{"issue":"1","key":"1064_CR13","doi-asserted-by":"publisher","first-page":"e0117334","DOI":"10.1371\/journal.pone.0117334","volume":"10","author":"P McEwan","year":"2015","unstructured":"McEwan P, Ward T, Bennett H, Kalsekar A, Webster S, Brenner M, et al. Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C. PLoS\u00a0One. 2015;10(1):e0117334.","journal-title":"PLoS\u00a0One"},{"issue":"2","key":"1064_CR14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"European Association for the Study of the Liver (EASL)","year":"2018","unstructured":"European Association for the Study of the Liver (EASL). EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461\u2013511.","journal-title":"J Hepatol"},{"key":"1064_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.puhe.2018.09.024","volume":"166","author":"M Munang","year":"2019","unstructured":"Munang M, Smit E, Barnett T, Atherton C, Tahir M, Atabani SF. Outcomes and costs of single-step hepatitis C testing in primary care, Birmingham, United Kingdom. Public Health. 2019;166:40\u20134.","journal-title":"Public Health"},{"issue":"1","key":"1064_CR16","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/S0618-8278(19)30974-0","volume":"70","author":"FG Garcia","year":"2019","unstructured":"Garcia FG, Dominguez R, Arboledas JCA, Casado M, Sanchez JM, P\u00e9rez FT, et al. FRI-229-reflex testing in patients with chronic hepatitis C in Spain improves healthcare outcomes and is cost effective. J Hepatol. 2019;70(1):e495\u20136.","journal-title":"J Hepatol"},{"issue":"12","key":"1064_CR17","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1093\/infdis\/jiy114","volume":"217","author":"FMJ Lamoury","year":"2018","unstructured":"Lamoury FMJ, Bajis S, Hajarizadeh B, Marshall AD, Martinello M, Ivanova E, et al. Evaluation of the Xpert HCV viral load finger-stick point-of-care assay. J Infect Dis. 2018;217(12):1889\u201396.","journal-title":"J Infect Dis"},{"key":"1064_CR18","volume-title":"Call to action for liver associations to advance progress towards viral hepatitis elimination: a focus on simplified approaches to HCV testing and cure","author":"AASLD, EASL, APASL, ALEH","year":"2019","unstructured":"AASLD, EASL, APASL, ALEH. Call to action for liver associations to advance progress towards viral hepatitis elimination: a focus on simplified approaches to HCV testing and cure. Boston: AASLD; 2019."},{"issue":"22","key":"1064_CR19","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","volume":"376","author":"M Bourliere","year":"2017","unstructured":"Bourliere M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134\u201346.","journal-title":"N Engl J Med"},{"key":"1064_CR20","unstructured":"World Health Organisation Regional Office for the Eastern Mediterranean (WHO EMRO). Viral hepatitis. Available at http:\/\/www.emro.who.int\/irq\/programmes\/hepatitis.html. Accessed 29 Apr 2019."},{"issue":"2","key":"1064_CR21","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/hep.22375","volume":"48","author":"HH Thein","year":"2008","unstructured":"Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418\u201331.","journal-title":"Hepatology"},{"issue":"3","key":"1064_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","unstructured":"Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161\u201376.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"1064_CR23","unstructured":"United Nations. Department of Economic and Social Affairs, Population Division (2007, 2010, 2018). Availabel at\u00a0 https:\/\/www.un.org\/development\/desa\/pd\/. Accessed 29 Apr 2019."},{"key":"1064_CR24","unstructured":"United Nations Statistics. Marriages and crude marriage rates (2007\u20132011). Available at\u00a0https:\/\/unstats.un.org\/unsd\/demographic\/products\/dyb\/dyb2011\/Table23.pdf. Accessed 29 Apr 2019."},{"key":"1064_CR25","unstructured":"World Health Organisation (WHO). Iraq, World Blood Donor Day. 2012. Available at http:\/\/www.emro.who.int\/irq\/iraq-events\/world-blood-donor-day.html. Accessed 29 Apr 2019."},{"key":"1064_CR26","unstructured":"U.S. Department of Commerce. Healthcare resource guide: Iraq 2018. Available at\u00a0https:\/\/2016.export.gov\/industry\/health\/healthcareresourceguide\/eg_main_116238.asp. Accessed 29 Apr 2019."},{"issue":"8","key":"1064_CR27","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jval.2011.06.006","volume":"14","author":"R Townsend","year":"2011","unstructured":"Townsend R, McEwan P, Kim R, Yuan Y. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health. 2011;14(8):1068\u201377.","journal-title":"Value Health"},{"issue":"1","key":"1064_CR28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/hep.26304","volume":"58","author":"P McEwan","year":"2013","unstructured":"McEwan P, Ward T, Yuan Y, Kim R, L\u2019Italien G. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology. 2013;58(1):54\u201364.","journal-title":"Hepatology"},{"issue":"1","key":"1064_CR29","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S0618-8278(19)30003-9","volume":"70","author":"A Mangia","year":"2019","unstructured":"Mangia A, Milligan S, Khalili M, Fagiuoli S, Shafran S, Carrat F, et al. GS-03-Global real world evidence of sofosbuvir\/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: integrated analysis of 12 clinical practice cohorts. J Hepatol. 2019;70(1):e2\u20133.","journal-title":"J Hepatol"},{"key":"1064_CR30","unstructured":"XE Corporation. XE currency converter: live rates: 1 USD to IQD. 2019. https:\/\/www.xe.com\/currencyconverter\/convert\/?Amount=1&From=USD&To=IQD. Accessed 12 Jul 2021."},{"key":"1064_CR31","unstructured":"United States Department of Labor: Bureau of Labor Statistics. Databases, tables & calculators by subject. 2019. https:\/\/data.bls.gov\/timeseries\/CUUR0000SAM?output_view=pct_12mths. Accessed 12 Jul 2021."},{"issue":"5","key":"1064_CR32","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/0272989X12454579","volume":"32","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7. Med Decis Mak. 2012;32(5):733\u201343.","journal-title":"Med Decis Mak"},{"issue":"4","key":"1064_CR33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-156-4-201202210-00378","volume":"156","author":"DB Rein","year":"2012","unstructured":"Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in US primary care settings. Ann Intern Med. 2012;156(4):263\u201370.","journal-title":"Ann Intern Med"},{"key":"1064_CR34","first-page":"w20026","volume":"149","author":"S Blach","year":"2019","unstructured":"Blach S, Schaetti C, Bruggmann P, Negro F, Razavi H. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland. Swiss Med Wkly. 2019;149:w20026.","journal-title":"Swiss Med Wkly"},{"issue":"1","key":"1064_CR35","doi-asserted-by":"publisher","first-page":"e0167770","DOI":"10.1371\/journal.pone.0167770","volume":"12","author":"DY Kim","year":"2017","unstructured":"Kim DY, Han K-H, Jun B, Kim TH, Park S, Ward T, et al. Estimating the cost-effectiveness of one-time screening and treatment for hepatitis C in Korea. PLoS\u00a0One. 2017;12(1):e0167770.","journal-title":"PLoS\u00a0One."},{"issue":"6","key":"1064_CR36","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jval.2013.07.005","volume":"16","author":"M Ruggeri","year":"2013","unstructured":"Ruggeri M, Coretti S, Gasbarrini A, Cicchetti A. Economic assessment of an anti-HCV screening program in Italy. Value Health. 2013;16(6):965\u201372.","journal-title":"Value Health."},{"issue":"4","key":"1064_CR37","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jhep.2015.05.015","volume":"63","author":"N Selvapatt","year":"2015","unstructured":"Selvapatt N, Ward T, Bailey H, Bennett H, Thorne C, See LM, et al. Is antenatal screening for hepatitis C virus cost-effective? A decade\u2019s experience at a London centre. J Hepatol. 2015;63(4):797\u2013804.","journal-title":"J Hepatol"},{"issue":"8","key":"1064_CR38","doi-asserted-by":"publisher","first-page":"e70319","DOI":"10.1371\/journal.pone.0070319","volume":"8","author":"AT Urbanus","year":"2013","unstructured":"Urbanus AT, van Keep M, Matser AA, Rozenbaum MH, Weegink CJ, van den Hoek A, et al. Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective? PLoS\u00a0One. 2013;8(8):e70319.","journal-title":"PLoS\u00a0One."},{"key":"1064_CR39","volume-title":"Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries. Geneva: World Health Organisation; 2018."},{"issue":"5","key":"1064_CR40","doi-asserted-by":"publisher","first-page":"e0125846","DOI":"10.1371\/journal.pone.0125846","volume":"10","author":"H Bennett","year":"2015","unstructured":"Bennett H, McEwan P, Sugrue D, Kalsekar A, Yuan Y. Assessing the long-term impact of treating hepatitis C virus (HCV)-infected people who inject drugs in the UK and the relationship between treatment uptake and efficacy on future infections. PLoS\u00a0One. 2015;10(5):e0125846.","journal-title":"PLoS\u00a0One"},{"issue":"8","key":"1064_CR41","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s10198-016-0844-8","volume":"18","author":"H Bennett","year":"2017","unstructured":"Bennett H, Gordon J, Jones B, Ward T, Webster S, Kalsekar A, et al. Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies. Eur J Health Econ. 2017;18(8):1001\u201311.","journal-title":"Eur J Health Econ"},{"key":"1064_CR42","unstructured":"World Health Organization. Hepatitis C. 2019. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed 12 Jul 2021."},{"issue":"12","key":"1064_CR43","doi-asserted-by":"publisher","first-page":"e003767","DOI":"10.1136\/bmjgh-2020-003767","volume":"5","author":"CE Boeke","year":"2020","unstructured":"Boeke CE, Adesigbin C, Agwuocha C, Anartati A, Aung HT, Aung KS, et al. Initial success from a public health approach to hepatitis C testing, treatment and cure in seven countries: the road to elimination. BMJ Glob Health. 2020;5(12):e003767.","journal-title":"BMJ Glob Health"},{"issue":"1","key":"1064_CR44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/hep.24656","volume":"55","author":"NK Martin","year":"2012","unstructured":"Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012;55(1):49\u201357.","journal-title":"Hepatology"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01064-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-021-01064-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01064-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T07:46:36Z","timestamp":1634283996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-021-01064-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1064"],"URL":"https:\/\/doi.org\/10.1007\/s40273-021-01064-z","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"28 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gilead Sciences provided support for this study. The funding agreement ensured the authors\u2019 independence in designing the study, interpreting the data and preparing the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Daniel M. Sugrue, Ryan Miller, Oliver Darlington, Bryony McNamara and Phil McEwan are employees of Health Economics and Outcomes Research Ltd. and received funding from Gilead Sciences to undertake the research outlined in this study. Sam Kozma and Eid Mansour are employees of Gilead Sciences. Bassem Asker, Rabah Asreah, Hiwa Abou Baker, Muslim Abdelkareem Inaya, Haydar Jamal, Haidar Jarallah, Ahmed Jassem and Raghad Jawad have no conflicts that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated or analysed during this study are included in this published article and its supplementary information files.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The code associated with this study is proprietary.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the design of the research and ensuring the final content was reflective of the Iraq setting. DS, BM and SK led the design and implementation of the research and to the writing of the manuscript. RM contributed to the design and implementation of the research, to the analysis of the data and to the writing of the manuscript. OD and PM provided senior review and technical expertise and contributed to the design of the research and to the writing of the manuscript. EM provided senior review and contributed to the design and implementation of the research. All named authors meet the International Committee of Medical Journal Editors criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole and have given final approval to the version to be published. As the guarantor and corresponding author, DS takes full responsibility for the work as a whole, and the decision to submit and publish the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}